To investigate the prognostic utility of left ventricular (LV)-global longitudinal strain (LV-GLS) in patients with hypertrophic cardiomyopathy (HCM) and an LV-ejection fraction (LVEF) of 50–60%. This retrospective cohort study included 349 patients with HCM and an LVEF of 50–60%. The primary outcome was a composite of cardiovascular death, including sudden cardiac death (SCD), and SCD-equivalent events. The secondary outcomes were SCD/SCD-equivalent events, cardiovascular death (including SCD), and all-cause death. The final analysis included 349 patients (mean age 59.2 ± 14.2 years, men 75.6%). During a median follow-up of 4.1 years, the primary outcome occurred in 26 (7.4%), while the secondary outcomes of SCD/SCD-equivalent events, cardiovascular death, and all-cause death occurred in 15 (4.2%), 20 (5.7%), and 34 (9.7%), respectively. After adjusting for age, atrial fibrillation, ischemic stroke, LVEF, and left atrial volume index, absolute LV-GLS (%) was independently associated with the primary outcome (adjusted HR 0.88, 95% CI 0.788–0.988, P = 0.029). According to receiver operating characteristic analysis, 10.5% is an optimal cutoff value for absolute LV-GLS in predicting the primary outcome. Patients with an absolute LV-GLS ≤ 10.5% had a higher risk of the primary outcome than those with an absolute LV-GLS > 10.5% (adjusted HR 2.54, 95% CI 1.117–5.787, P = 0.026). Absolute LV-GLS ≤10.5% was an independent predictor for each secondary outcome (P < 0.05). LV-GLS was an independent predictor of a composite of cardiovascular death, including SCD/SCD-equivalent events, in patients with HCM and an LVEF of 50–60%. Therefore, LV-GLS can help in risk stratification in these patients.